Shopping Cart
Remove All
Your shopping cart is currently empty
VGX-1027
🥰Excellent
Catalog No. T1813Cas No. 6501-72-0
Alias VGX1027, VGX 1027, GIT 27
VGX-1027 (GIT 27) is an isoxazole compound with various immunomodulatory properties.
VGX-1027
🥰Excellent
Purity: 99.86%
Catalog No. T1813Alias VGX1027, VGX 1027, GIT 27Cas No. 6501-72-0
VGX-1027 (GIT 27) is an isoxazole compound with various immunomodulatory properties.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | $41 | In Stock | In Stock | |
| 25 mg | $85 | In Stock | In Stock | |
| 50 mg | $137 | In Stock | In Stock | |
| 100 mg | $220 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $30 | In Stock | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:99.86%
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
| Description | VGX-1027 (GIT 27) is an isoxazole compound with various immunomodulatory properties. |
| In vitro | VGX-1027 enhances survival rates and ameliorates clinical and histopathological signs in the NZB/NZW F1 model of systemic lupus erythematosus, thereby improving disease progression. It prevents the spontaneous development of Type 1 diabetes in NOD mice and counters the acceleration of diabetes induced either by cyclophosphamide assault or by the adoptive transfer of diabetogenic spleen cells in NOD mice. Furthermore, VGX-1027 reduces clinical symptoms of diabetes induced by MLD-STZ and inhibits pathological histological changes in the pancreas. |
| In vivo | VGX-1027 exhibits inhibitory effects on the proliferation of gut bacterial antigen-reactive CD4+ CD25- T cells in vitro. It significantly suppresses the accumulation of TNF-α and nitrites induced by IL-1β/IFN-γ, and notably enhances cell survival by interfering with the toxic effects of cytokines. |
| Synonyms | VGX1027, VGX 1027, GIT 27 |
| Molecular Weight | 205.21 |
| Formula | C11H11NO3 |
| Cas No. | 6501-72-0 |
| Smiles | OC(=O)CC1CC(=NO1)c1ccccc1 |
| Relative Density. | no data available |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 20.5 mg/mL (99.9 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (9.75 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy VGX-1027 | purchase VGX-1027 | VGX-1027 cost | order VGX-1027 | VGX-1027 chemical structure | VGX-1027 in vivo | VGX-1027 in vitro | VGX-1027 formula | VGX-1027 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.